Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score:16

www.lung.org

State Data | Alabama - 2 days

Mashup Score:16

Understand lung cancer burden in Alabama by looking at the measures of new cases, survival rates, early diagnosis, surgical treatment, lack of treatment, screening,...

Oncology News...

This nonrandomized clinical trial evaluates the treatment outcomes and safety of mobocertinib treatment in patients with previously treated EGFR exon 20 insertionā€“positive metastatic nonā€“small...

  • Mobocertinib,an oral tyrosine kinase inhibitor vs EGFR exon 20 insertions, demonstrated 28% response rate in platinum-pretreated patients w advanced NSCLC harboring an EGFR exon 20 insertion mutation, with primarily GI & dermatologic side effects https://t.co/ABjJhfqKMI #LCSM - view on twitter

Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the...

Gene fusions involving ALK, ROS1, RET, and NTRK are now established targets in NSCLC, for which highly effective and well-tolerated kinase inhibitors are the...

  • Gene fusions are established targets in #NSCLC, for which highly effective & well-tolerated kinase inhibitors are the preferred initial therapy. A growing body of evidence suggests fusions in NRG1 will emerge as another relevant genomic target. More: https://t.co/iuTtXgZWrt #LCSM - view on twitter

By The ASCO Post Staff Posted: 10/15/2021 12:49:00 PM Last Updated: 10/15/2021 12:12:41 PM On October 15, the U.S. Food and Drug Administration (FDA)...

Sandra Duncan, RN, BSN, shares her experience with the CheckMate-73L trial of ipilimumab/nivolumab in nonā€“small cell lung cancer, efforts made to overcome communication challenges,...

The data from the phase 3 ADAURA trial with adjuvant osimertinib are among the most significant to read out in the past year in...

The investigational next-generation ROS1/NTRK inhibitor taletrectinib was found to elicit encouraging responses with an acceptable toxicity profile in patients with ROS1-positive nonā€“small cell lung...

Alexander I. Spira, MD, PhD, FACP, discusses impactful data from the 2021 ESMO Congress in lung...